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http://dx.doi.org/10.1016/j.jds.2012.0Abstract Background/purpose: D-Glucosamine hydrochloride (DGL) has a variety of biolog-
ical activities and is noted as a nutritional supplement that is effective for improvement
and care of various disorders, such as osteoarthritis and atherosclerosis. Although, it has been
reported that DGL has a significant pain relief effect in treating osteoarthritis, little is known
about its effect on dental pain. The applicability of DGL as a medicament to control pain in
pulpalgia has not been reported. In this study, using an in vitro rat mandible-inferior alveolar
nerve preparation (jaw-nerve preparation), the effect of DGL on nociceptive responses in the
tooth pulpal nerve was examined.
Materials and methods: The effect of DGL on nociceptive responses for 20 male Wistar albino
rats was evaluated using an in vitro jaw-nerve preparation. Bradykinin (BK), used as a chemical
nociceptive stimulant, was applied near the exposed tooth pulp. Sixty seconds after BK appli-
cation, the surface of the exposed pulp was treated with DGL solution or physiological saline
(control).
Results: The nerve firing rate was 2.06 0.21 Hz (nZ 10) after 5 minutes of saline application,
and 0.76 0.16 Hz (nZ 10) after 5 minutes of DGL application. The DGL group showed signif-
icantly lower nerve firing rate than the control group.
Conclusion: BK-induced nociceptive responses were significantly suppressed by direct applica-
tion of DGL. Our results suggest that DGL might have a pain relief effect in dental pain.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by Else-
vier Taiwan LLC. All rights reserved.of Cariology, Nagasaki University, Graduate School of Biomedical Sciences, Sakamoto 1-7-1, Nagasaki
agasaki-u.ac.jp (K. Kaida).
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D-Glucosamine hydrochloride (DGL), a natural amino
monosaccharide, is produced by totally hydrolyzing chitin
with hydrochloric acid. Chitin is a polysaccharide found in
the outer skeletal tissue of crabs, shrimps and lobsters,1
and is the main productive source of chitosan.
DGL has a variety of biological activities, such as
suppression of the neutrophil functions,2 progression of
adjuvant arthritis, and platelet aggregation,3 and activa-
tion of intestinal epithelial cells4 and of synoviocytes.5
Furthermore, DGL has been used as an effective medica-
ment in various fields of medicine and dentistry.6,7 For
example, DGL is an attractive candidate for adjunctive
therapy in arthritis, exhibiting not only chondroprotective
action, but also anti-inflammatory actions via the suppres-
sion of neutrophil functions.2 DGL also has a significant
antipain effect in treating osteoarthritis,8e12 which is
considered to be a diseasewith lowexpectations of the value
of treatment.13,14 Nonsteroidal anti-inflammatory drugs
(NSAIDs) are commonly used to treat osteoarthritis but have
major adverse effects15 and might even worsen the symp-
toms.16 Several short- and long-term clinical trials in osteo-
arthritis have shown the significant effect of DGL.17e19
Therefore, DGL is widely used in an attempt to suppress
the pain concerned with disability of osteoarthritis.20
In dental fields, DGL promotes tissue regeneration on
dental pulp wounds.21 Evidence for this includes: (1) alka-
line phosphatase activity is increased after DGL applica-
tion22; (2) DGL enhances the expression of bone
morphogenetic protein-2 mRNA22; (3) DGL inhibits
interleukin-8 secretion from pulp fibroblast21; and (4) DGL
induces the initial anti-inflammatory reaction in the pulp
tissue.21
The present study was undertaken to evaluate the
possibility of DGL as a medicament to control pulpalgia,
because severe tooth pain is generally observed in the
clinical case of pulpalgia.
Materials and methods
The methods described here follow the ethical guidelines
and received approval from the Animal Welfare Committee
of Nagasaki University (No. 0806090666, 2008-2011).
Preparation
Twenty male Wistar albino rats (body weight about 200 g)
were used in the present study. The animals were deeply
anesthetized with thiamylal sodium (60 mg/kg, i.p., Isozol;
Nippon-Iko Pharmacy, Toyama, Japan). An in vitro jaw-
nerve preparation23 was slightly modified to enable easy
direct access to the dental pulp (Fig. 1). The mandible was
divided into the right and left halves at the central suture
using a pair of scissors, and surrounding masticatory
muscles were completely removed using surgical scissors.
Then, the inferior alveolar nerve was identified at the
foramen mandibulae on one side and isolated from the
surrounding tissue. The mandible on one side was removed
together with the inferior alveolar nerve by cutting the
temporomandibular joint. Finally, about 20 mm of inferioralveolar nerve trunk was obtained from the foramen man-
dibulae and proximal end of the nerve was ligated with
cotton thread. A small hole at the center part of the incisor
tooth was carefully made to expose the dental pulp using
a dental bur (round bur #3; Meisinger, Neuss, Germany).
Drug solutions
Modified Krebs-Henseleit solution consisted of 110.9 mM
NaCl, 4.8 mM KCl, 2.5 mM CaCl2 1.2 mM MgSO4, 1.2 mM
KH2PO4, 22.4 mM NaHCO3, and 20 mM glucose was used for
perfusion.
Bradykinin acetate salt (BK; Sigma, St. Louis, MO, USA)
was dissolved in sterile physiological saline (Otsuka Phar-
maceutical Co, Tokyo, Japan). A 104 M BK solution was
used to stimulate tooth pulpal nociceptors chemically.
DGL was supplied by Koyo Chemical Co. (Osaka, Japan).
The molecular weight of the DGL used in this experiment
was about 215 Da. A 10% (w/v) solution was prepared by
dissolving DGL powder in sterile physiological saline.
Chamber design
As shown in Fig. 1, a chamber (total volume: 147 mL) was
made with a plastic plate (thickness: 2 mm). The chamber
room was separated into two pools (test pool: 84 mL; oil
pool: 63 mL) by a thin plastic plate (thickness: 1 mm), at the
center of which a small hole (diameter: 1.5 mm) was drilled
to pass the trunk of the inferior alveolar nerve. A hard
rubber bed was attached to the bottom of the test pool to
prevent damage of the preparation.
Recording procedures
The mandible was placed in the test pool and the inferior
alveolar nerve was passed through a hole at the center of
the partition plate, and placed in the recording chamber
(oil pool) and fixed to the wall of the chamber with the
cotton thread. The hole at the center of the partition plate
was capped by Vaseline. The inferior alveolar nerve in the
oil pool was desheathed by slipping off the epineurium, and
was slightly pulled to give a tension for insertion of the
recording electrodes. The oil pool was filled with liquid
paraffin to immerse the inferior alveolar nerve. The test
pool was perfused (0.3 mL/s) with modified Krebs-Henseleit
solution. The solution was saturated with a gas mixture of
O2:CO2 (95%:5%).
To compare the data quantitatively, the fluid was heated
to maintain the temperature at 31 C with a feedback-
controller; this temperature was used because, in rats, it
is the mean temperature of peripheral tissue, such as
surface facial skin or oral structures.
To record single fiber responses, a tungsten microelec-
trode (tip impedance 10e12 MU at 10 kHz; A-M Systems,
Carlsborg, Washington, USA) was inserted into the inferior
alveolar nerve trunk using a micromanipulator (MP-1; Nar-
ishige, Tokyo, Japan). The action potential was fed into
a high-impedance, low-noise amplifier (DAM-80; WPI
Instruments, New Haven, CT, USA) and displayed on
a computer through the CED 1401 interface (Cambridge
Electronic Design Ltd., Cambridge, UK). Spike analysis was
Figure 1 Schematic presentation of the chamber set up for the jaw-nerve preparation (see text for details).
Figure 2 The firing rate (Hz) just after preparation for the
control and DGL groups. There were no significant differences
(P> 0.05). Dots show the firing rate. Vertical bars indicate
standard errors.
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2.01).
To test chemical nociceptive sensitivity in the pulpal
nerve, we selected only C-fiber responses for quantitative
analysis and observed one unit/rat to prevent sensitization
of the nociceptor. As criteria for C-fiber in the tooth pulp,
two characteristics were adopted: (1) it is reported that C-
fiber terminals are located in the center core of the pulp24;
(2) spontaneous discharge of the C-fiber had a mean
frequency of 1.6 0.5 Hz (range, <2.0 Hz) as reported by
Xiao and Bennett.25 According to these criteria, we
recorded unit responses from the center part of the tooth
pulp having initial firing frequency of <2.0 Hz.
BK was used as a chemical nociceptive stimulant and
applied into the test chamber near the exposed tooth pulp
at a rate of 0.1 mL/s. Sixty seconds after BK application,
the surface of the exposed pulp was treated with DGL
solution or with physiological saline (control).
Statistical analysis
The obtained data were evaluated using StatView software
Version 5.0 (SAS Institute Inc. Cary, NC, USA). Values are
expressed as means SE, and the difference between the
control and DGL groups was compared using an unpaired
Student t test. A P value of <0.05 was considered to be
significant.
Results
A total of 20 single unit responses were obtained. Initially,
a majority of the units were spontaneously firing at
0.1e2.0 Hz. This low spontaneous activity was a good
indicator showing that the tissue damage level induced by
surgical removal of the jaw or making a small hole on the
incisor was not so severe for electrophysiological record-
ings. The firing rate just after preparation in the control
group was 0.91 0.12 Hz (nZ 10), and that in the DGL
group was 0.96 0.16 Hz (nZ 10). There were no signifi-
cant differences in the initial firing rate before BK appli-
cation between the control and DGL groups (Fig. 2)
Fig. 3 shows a typical example of pulpal unit responses to
BK applications and the effect of saline (A) andDGL (B) on the
BK-inducedexcitatory responses. Histograms below rawdata
show the number of impulses/10 seconds. Upward arrowsindicate the time of BK (filled) and DGL (open) application. It
was observed that BK application significantly increased
spike responses, indicating that nociceptive responses were
evoked. After DGL application, BK-induced excitatory
responses were gradually decreased; however, saline appli-
cation had no effect.
Fig. 4 shows a summary of the time course of the effect
of DGL on the BK-evoked responses. It was observed that
the firing rate in the control group (open circle) kept
increasing after saline application. By contrast, the firing
rate in the DGL group (filled circle) was decreased after
DGL application. The frequency in the control group was
2.06 0.21 Hz (nZ 10) after 5 minutes of saline applica-
tion, while that in the DGL group was 0.76 0.16 Hz
(nZ 10) after 5 minutes of DGL application. The DGL group
showed significantly lower frequency than the control
groups (asterisks; P< 0.05).Discussion
Several studies have shown that DGL has pain relief effects
through anti-inflammation and wound healing.2,3,21,26,27
The molecular weight of DGL is about 215, and it is
thought to dissolve easily at the applied site although this
Figure 3 Typical examples of pulpal unit responses to BK applications and the effect of (A) saline and (B) DGL on the BK-induced
responses. Arrows indicate the time points of BK (filled arrows) and saline or DGL (open arrows) applications.
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tissue when used as part of a dressing material.
Very mild postoperative inflammation is characteristic
after dressing tooth pulp with a high concentration of
DGL.28 In this study we used a 10% (w/v) solution prepared
by dissolving DGL powder in sterile physiological saline. DGL
appeared to induce no inflammatory reaction at this
concentration, because no enhancement of the spike
responses was observed after DGL application, as shown in
Fig. 4.Figure 4 Effect of DGL on the BK-induced responses. Arrows
indicate the time points of BK and DGL applications, respec-
tively. The DGL group showed significantly lower frequency
than the control groups after 240e420 seconds. *P< 0.05.
Vertical bars indicate standard errors.The effect of DGL on dental pain has been reported
rarely. The present study was undertaken to evaluate the
effects of DGL directly applied into exposed dental pulp,
showing that DGL suppressed nociceptive responses evoked
by BK application in the tooth pulp.
An in vitro preparation has the advantages controlling
quantitatively all environmental variables surrounding the
oral tissue and allowing direct application of chemical
solutions onto the receptive field.22 Therefore, we inves-
tigated the analgesic effect of DGL on the tooth pulp
“directly”, although many clinical trials have shown the
effect of DGL by oral administration.17e19
The precise mechanisms of antinociceptive action of
DGL are still unknown; however, glucosamine-induced
antinociception is presumed to be caused by anti-
inflammatory actions. Neutrophils, which are thought to
be primary defenders in bacterial infections, are implicated
in the destructive, inflammatory responses, and glucos-
amine suppresses the functions of the neutrophils, thereby
possibly exhibiting anti-inflammatory actions.2 Further-
more, in rats, glucosamine is reported to suppress the
progression of adjuvant arthritis by inhibiting the chronic
phase of inflammatory reaction and also suppress the
production of inflammatory mediations (NO and PGE2).
3
Therefore, glucosamine is potentially a novel anti-
inflammatory agent.
In addition, it has been reported that DGL reduces the
elementary current amplitude and increases the mean
channel open time.29 Because DGL has a weak binding site
in the channel itself,29 the channel cannot be closed.29
Voltage-gated sodium channels, which are necessary for
electrogenesis and nerve impulse conduction, can be
72 K. Kaida et aldynamically regulated after nerve injury or peripheral
inflammation and play important roles in modulating neural
excitability.30,31 DGL might have an antinociceptive effect
by the binding to sodium channels, resulting in a longer
open time.
It has been reported that DGL has a significant pain relief
effect in treating osteoarthritis,11 in spite of negative
results for temporomandibular joint disorder.12 Osteoar-
thritis, developing as a result of progressive destruction of
articular cartilage, is the most common joint disease and
the leading cause of pain and physical disability in the
elderly population. High blood pressure and diabetes are
major risk factors for cardiovascular disease in this pop-
ulation. They have a high prevalence of multiple diseases
that must be managed at the same time and often require
the use of different drugs. Conventional pharmacological
approaches to symptom management in osteoarthritis
involve NSAIDs. However, there are accumulating data
showing that any of these pharmaceutical drugs frequently
produce insufficient benefit, with an associated risk of
untoward side effects.32,33 For example, NSAIDs can
increase blood pressure. Glucosamine appears to be an
attractive alternative, because it is a naturally occurring
compound in the articular cartilage, and DGL is a symptom
modifying drug with good evidence for favorable long-term
effects on disease progression. DGL has a significant pain
relief effect in treating osteoarthritis. Therefore, it is
widely used in an attempt to suppress the pain and to treat
disability of osteoarthritis.
The results of our study show that DGL might have a pain
relief effect in dental pain. These findings led us to
examine the application of DGL to dental analgesia.
Furthermore, a recent systematic review showed that
glucosamine appears to be just as effective as ibuprofen
for the management of temporomandibular joint
osteoarthritis.34
Use of glucosamine to treat disorders in the orofacial
area is thought to be a possible alternative with a promising
future. Also, further experiments may be necessary to
evaluate the analgesic effect of DGL in cellular level and
animal models.References
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